Lindenhofgruppe Geschäftsbericht 2018

Thema Fachgebiet Ansprechperson Lindenhofgruppe Kooperations- partner / Sponsor A Long-Term Extension Study to Evaluate the Safety of Filgotinib in Subjects with Crohn’s Disease (Gilead_GS- US-419-3896_MC_OL) Gastroentero- logie Prof. Dr. med. Frank Seibold Gilead Sciences Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study of Oral Ozanimod as Induction and Main- tenance Therapy for Moderately to Severely Active Crohn’s Disease (Ozanimod_RPC01-3201_Induction_MC + Ozanimod_ RPC01-3203_Maintenance_MC) Gastroentero- logie Prof. Dr. med. Frank Seibold Celgene ACRE, A Multi-Center, Multi-National, Randomised, Double- Blind, Placebo Controlled, Parallel Group, Phase IIa Study to Evaluate the Efficacy, Safety and Tolerability of an Anthocyanin Rich Extract (ACRE) in Patients with Ulcerative Colitis Gastroentero- logie Prof. Dr. med. Frank Seibold Swiss IBDnet A Phase 2a, Double-Blind, Randomized, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Oral Pf-06651600 and Pf-06700841 as Induction and Open Label Extension Treatment in Subjects With Moderate to Severe Crohn’s Disease (Pfizer Icon B7981007_Pizzicato_ 1125_MC) Gastroentero- logie Prof. Dr. med. Frank Seibold Pizer A Phase III, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Etrolizumab as an Induction and Maintenance Treatment for Patients with Moderately to Severely Active Crohn’s Disease (ETRO_144) Gastroentero- logie Prof. Dr. med. Frank Seibold Hoffmann-La Roche / Genen- tech An Open-Label Extension and Safety Monitoring Study of Patients with Moderately to Severely Active Crohn’s Disease Previously Enrolled in the Etrolizumab Phase III (ETRO_145) Gastroentero- logie Prof. Dr. med. Frank Seibold Hoffmann-La Roche/ Genen- tech Phase III, Double-Blind, Placebo-controlled, Multicenter Study of the Efficacy And Safety of Etrolizumab during Induc- tion and Maintenance in Patients with Moderate to Severe Active Ulcerative Colitis who have been Previously Exposed to TNF Inhibitors (ETRO_950) Gastroentero- logie Prof. Dr. med. Frank Seibold Hoffmann-La Roche/ Genen- tech An Open-Label Extension and Safety Monitoring Study of Moderate to Severe Ulcerative Colitis Patients Previously Enrolled in Etrolizumab Phase II/III Studies (ETRO_951) Gastroentero- logie Prof. Dr. med. Frank Seibold Hoffmann-La Roche/ Genen- tech Geschäftsbericht 2018 78 Lehre und Forschung